Advertisement
Advertisement
CHRS
Coherus Oncology, Inc. Common Stock
1.48
USDSponsored
+0.09
+6.47%
Jun 18, 15:59 UTC -4
Closed
After-Market
1.44
-0.04
-2.77%
CHRS Earnings Reports
Positive Surprise Ratio
CHRS beat 17 of 42 last estimates.
40%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$14.90M
/-$0.14
Implied change from Q1 26 (Revenue/ EPS)
+21.00%
/-44.00%
Implied change from Q2 25 (Revenue/ EPS)
+45.26%
/-58.82%
Coherus Oncology, Inc. Common Stock earnings per share and revenue
On May 11, 2026, CHRS reported earnings of -0.25 USD per share (EPS) for Q1 26, beating the estimate of -0.27 USD, resulting in a 10.33% surprise. Revenue reached 12.31 million, compared to an expected 14.63 million, with a -15.85% difference. The market reacted with a -12.31% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.14 USD, with revenue projected to reach 14.90 million USD, implying an decrease of -44.00% EPS, and increase of 21.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
Prenetics Global Limited Class A Ordinary Share
Report Date
Jun 10, 2026 For Q1 26
Estimate
-$1.10
Actual
-$1.61
Surprise
-45.36%
Anixa Biosciences, Inc.
Report Date
Jun 10, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+21.61%
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
What were Coherus Oncology, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Coherus Oncology, Inc. Common Stock reported EPS of -$0.25, beating estimates by 10.33%, and revenue of $12.31M, -15.85% below expectations.
How did the market react to Coherus Oncology, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -12.31%, changed from $1.95 before the earnings release to $1.71 the day after.
When is Coherus Oncology, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Coherus Oncology, Inc. Common Stock's next earnings report?
Based on 6
analysts, Coherus Oncology, Inc. Common Stock is expected to report EPS of -$0.14 and revenue of $14.90M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement